Moogene Medi Co. Ltd.

Moogene Medi Co. Ltd.

KKRX:322970
1,839.00
KRW
+29.00
(+1.60%)
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

CEO
Tae-Jong Yoon
Full Time Employees
16
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Hanam-si South Korea
IPO Date
Jun 24, 2020
Business
Moogene Medi Co. Ltd. is a South Korea-based biopharmaceutical and nanomedicine company that specializes in the development of lipid nanoparticle (LNP) drug delivery systems, CRISPR/Cas9 gene-editing therapeutics, and transdermal medical technologies. Founded in 2016 and headquartered in Hanam-si, Gyeonggi-do, South Korea, the company operates dedicated research and development laboratories as well as Good Manufacturing Practice (GMP) pilot production facilities. Moogene Medi operates primarily across biopharmaceuticals, transdermal drug delivery systems, and specialized cosmeceutical ingredients. Its core product and development pipeline includes HUTERA D (AD-303), a topical lipid nanoparticle-encapsulated dutasteride formulation designed for the targeted treatment of androgenetic alopecia (male pattern baldness) with reduced systemic side effects; DREC-21, an oncology therapeutic candidate utilizing LNP-delivered gene-editing tools for colorectal cancer; PDAC-11, a dual-gene-editing therapeutic program targeting pancreatic ductal adenocarcinoma; proprietary LNP formulations for mRNA vaccines and small-molecule therapeutics; ultrasound-assisted microbubble transdermal drug delivery devices developed to enhance active ingredient penetration through sonoporation; and functional cosmetic raw materials and specialized cosmeceutical formulations, including clinical scalp serums, ampoules, and anti-aging skincare solutions supplied to dermatological clinics and aesthetic salons. In recent developments, Moogene Medi has advanced its lead therapeutic program, AD-303 (HUTERA D), through Phase 1/2a clinical trials following regulatory clearance from the South Korean Ministry of Food and Drug Safety, supported by granted patents in both South Korea and the United States for its topical LNP alopecia delivery technology. To accelerate clinical translation and commercialization, the company has established strategic co-development agreements and alliances with major domestic pharmaceutical companies, including Yuhan Corporation, JW Shin Pharmaceutical, Chong Kun Dang, and Medica Korea, and entered into a strategic business agreement with Daehwa Pharmaceutical to collaborate on nano-formulation drug development. Additionally, Moogene Medi has expanded its in-house GMP manufacturing infrastructure to support pilot-scale clinical supply and contract nanomedicine development services.